InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a report released on Friday. The brokerage set a “sell” rating on the stock.

Separately, Lake Street Capital began coverage on shares of InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective on the stock.

InspireMD Stock Up 1.8 %

Shares of InspireMD stock opened at $2.86 on Friday. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.42. The firm has a market capitalization of $74.60 million, a PE ratio of -3.81 and a beta of 1.00. The stock’s fifty day moving average is $2.79 and its 200-day moving average is $2.74.

InspireMD (NYSE:NSPR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The firm had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same quarter last year, the business posted ($0.15) EPS. Analysts expect that InspireMD will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Affiance Financial LLC raised its holdings in InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after purchasing an additional 5,376 shares during the period. Parkman Healthcare Partners LLC bought a new position in shares of InspireMD in the 3rd quarter valued at about $279,000. Essex Investment Management Co. LLC bought a new position in shares of InspireMD in the fourth quarter valued at $191,000. Legato Capital Management LLC acquired a new position in shares of InspireMD during the 4th quarter worth about $47,000. Finally, Renaissance Technologies LLC acquired a new position in InspireMD during the fourth quarter worth approximately $27,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.